The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing ...
TORONTO, March 27, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...
Chinese researchers have built a machine-learning nomogram that combines biparametric MRI radiomics, clinical variables, and ...
InvestorsHub on MSN
Profound Medical and Telix Pharmaceuticals partner to advance prostate cancer imaging and treatment education
Profound Medical (NASDAQ:PROF) and Telix Pharmaceuticals (NASDAQ:TLX) have signed a co-education agreement aimed at increasing physician awareness of how advanced diagnostic imaging can support ...
MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests A new meta-analysis by investigators from Brigham and ...
A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society ...
Using prostate MRI before a biopsy is a real advance in prostate cancer diagnosis. Multiple randomized trials have shown that imaging the prostate first and then targeting suspicious lesions finds ...
MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...
A prospective study shows PSMA PET/CT-guided targeted biopsy detects clinically significant prostate cancer in 37 percent of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results